Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.69 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
| ▸ | ABHD6 | Q9BV23 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | IGF1R | P08069 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | BCL2 | P10415 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29586905 | 1.00 | NR1H2 (0.69) | NR1H2ESR2MAPK1HDAC1DDB1 | |
| SCHEMBL21326100 | 0.95 | ESR2 (0.70) | NR1H2ESR2MAPK1HDAC1DDB1 | |
| SCHEMBL29587366 | 0.95 | ESR2 (0.70) | NR1H2ESR2MAPK1HDAC1DDB1 | |
| SCHEMBL38653719 | 0.89 | ESR2 (0.54) | NR1H2ESR2MAPK1HDAC1DDB1 | |
| SCHEMBL23253904 | 0.89 | ESR2 (0.54) | NR1H2ESR2MAPK1HDAC1DDB1 | |
| SCHEMBL31335550 | 0.85 | NR1H2 (0.60) | NR1H2ESR2MAPK1HDAC1DDB1 | |
| SCHEMBL17813389 | 0.84 | ESR2 (0.69) | NR1H2ESR2MAPK1HDAC1DDB1 | |
| SCHEMBL12252190 | 0.83 | NR1H2 (0.74) | NR1H2ESR2MAPK1HDAC1DDB1 | |
| SCHEMBL545619 | 0.83 | ESR2 (0.90) | NR1H2ESR2MAPK1HDAC1DDB1 | |
| SCHEMBL29372093 | 0.83 | ESR2 (0.90) | NR1H2ESR2MAPK1HDAC1DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109863145-B | Novel tetrahydroisoquinoline and tetrahydronaphthyridine compounds for the treatment and prevention of hepatitis b virus infection | 豪夫迈·罗氏有限公司 | 2022-04-12 | — | — | CN | disclosed |
| US-11124495-B2 | Tetrahydroisoquinolines and terahydronaphthyridines for the treatment of hepatitis B virus infection | HOFFMANN-LA ROCHE, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-11124495-B2 | Tetrahydroisoquinolines and terahydronaphthyridines for the treatment of hepatitis B virus infection | HOFFMANN-LA ROCHE, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| EP-3535256-B1 | NOVEL TETRAHYDROISOQUINOLINES AND TERAHYDRONAPHTHYRIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2020-12-02 | — | — | EP | disclosed |
| EP-3535256-B1 | NOVEL TETRAHYDROISOQUINOLINES AND TERAHYDRONAPHTHYRIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2020-12-02 | — | — | EP | disclosed |
| US-20190276433-A1 | NOVEL TETRAHYDROISOQUINOLINES AND TERAHYDRONAPHTHYRIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2019-09-12 | — | — | US | disclosed |
| US-20190276433-A1 | NOVEL TETRAHYDROISOQUINOLINES AND TERAHYDRONAPHTHYRIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2019-09-12 | — | — | US | disclosed |
| EP-3535256-A1 | NOVEL TETRAHYDROISOQUINOLINES AND TERAHYDRONAPHTHYRIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2019-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11124495-B2 | Tetrahydroisoquinolines and terahydronaphthyridines for the treatment of hepatitis B virus infection | HCCS, HAVCR2, ZC3HAV1 | NR1H2 34/4885ESR2 1515/4885MAPK1 3709/4885 |
| US-20190276433-A1 | NOVEL TETRAHYDROISOQUINOLINES AND TERAHYDRONAPHTHYRIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HAVCR2, HCCS, RECQL | NR1H2 41/4885ESR2 1543/4885MAPK1 3449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.